Adjuvant Capital

Adjuvant is a new type of venture capital firm. We invest in the most promising life science technologies for high-burden public health challenges. We see enormous opportunities in historically overlooked market segments, and we leverage our unique expertise to translate these opportunities into social and financial returns for our investors. Adjuvant Capital is a life sciences investment firm focused on global health. We make $10-$25 million investments in ambitious companies targeting opportunities in high burden and neglected disease. Our mission is simple: use venture capital strategies to deploy capital in the most promising public health technologies and ensure they are made accessible to those who need them most. We invest in innovative technologies to address high-burden and neglected infectious diseases, maternal and child health, nutrition, and reproductive and sexual health.